type: timeline_event
The dialysis industry's duopoly of DaVita and Fresenius (controlling 67% of 6,700 facilities and 90% of industry revenue in the $25 billion market) operates systematic schemes to maximize profits by steering patients toward in-clinic dialysis and commercial insurance rather than superior, cheaper alternatives. Home dialysis is up to 5 times cheaper than in-clinic treatment, favored by most nephrologists, less stressful for patients, and produces higher job satisfaction and lower burnout for nurses, yet DaVita and Fresenius strongly discourage patients from pursuing this option because it reduces facility revenue. Research shows that when the duopoly acquires independent clinics, hospitalization rates increase 6%, death rates rise 3%, and most alarmingly, transplant rates during patients' first year fall almost 10%. The industry also allegedly uses American Kidney Fund donations to steer low-income patients from government insurance to private commercial insurance, exploiting the 4x reimbursement difference: Medicare pays approximately $250-300 per treatment while private insurers pay over $1,000 per treatment (sometimes $100,000-200,000 annually per patient). Analysts estimate this insurance steering scheme generates 30-45% of the giants' annual pre-tax income. Senator Blumenthal describes the industry as 'ripe with predatory, monopolistic potential practices' and calls for FTC enforcement action. Federal data review finds one-third of dialysis clinics (nearly 2,500 of 7,600 nationwide) fail to meet federal standards, with average scores of only 60 out of 100 points. The concentration exceeds that of primary care, home health, and health insurance markets, giving duopoly extraordinary power over pricing and treatment decisions for 550,000 Americans with kidney failure who depend on dialysis for survival, enabling profit extraction that demonstrably harms patient outcomes while enriching corporate owners.